Your browser doesn't support javascript.
loading
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko, Otto; O'Connor, Caitlin M; Kulesskiy, Evgeny; Sangodkar, Jaya; Aakula, Anna; Izadmehr, Sudeh; Yetukuri, Laxman; Yadav, Bhagwan; Padzik, Artur; Laajala, Teemu Daniel; Haapaniemi, Pekka; Momeny, Majid; Varila, Taru; Ohlmeyer, Michael; Aittokallio, Tero; Wennerberg, Krister; Narla, Goutham; Westermarck, Jukka.
Afiliación
  • Kauko O; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • O'Connor CM; Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
  • Kulesskiy E; TuBS and TuDMM Doctoral Programmes, University of Turku, 20520 Turku, Finland.
  • Sangodkar J; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106-7285, USA.
  • Aakula A; Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
  • Izadmehr S; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Yetukuri L; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • Yadav B; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Padzik A; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • Laajala TD; Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
  • Haapaniemi P; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • Momeny M; Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
  • Varila T; Department of Mathematics and Statistics, University of Turku, 20520 Turku, Finland.
  • Ohlmeyer M; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • Aittokallio T; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • Wennerberg K; Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
  • Narla G; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Westermarck J; Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland.
Sci Transl Med ; 10(450)2018 07 18.
Article en En | MEDLINE | ID: mdl-30021885
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Resistencia a Antineoplásicos / Quinasas de Proteína Quinasa Activadas por Mitógenos / Inhibidores de Proteínas Quinasas / Proteína Fosfatasa 2 / Neoplasias Pulmonares / Mutación Límite: Animals / Humans / Male Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Finlandia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Resistencia a Antineoplásicos / Quinasas de Proteína Quinasa Activadas por Mitógenos / Inhibidores de Proteínas Quinasas / Proteína Fosfatasa 2 / Neoplasias Pulmonares / Mutación Límite: Animals / Humans / Male Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Finlandia